Jessica C Lowney

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study.

A. LaCasce, S. Tyekucheva, M. Davids, 2021, The Lancet. Oncology.